Ticker

No recent analyst price targets found for SOLTF.

Latest News for SOLTF

Nxera Joins OpenFold AI Research Consortium Alongside Leading Global Pharmaceutical and AI Companies to Accelerate AI-enabled Drug Discovery

Tokyo, Japan and Cambridge, UK, 10 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) announces that it has joined OpenFold, a non-profit AI research consortium that promotes the development of open-source AI software tools for biology and drug discovery. Technology companies, including Amazon Web Services, Microsoft and NVIDIA, participate in OpenFold as supporting members and the consortium has expanded…

GlobeNewsWire • Jun 10, 2026
Nxera's Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea

Tokyo, Japan and Cambridge, UK, 2 June 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)  announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization…

GlobeNewsWire • Jun 1, 2026
Nxera's President & CEO to Participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference 2026

Tokyo, Japan and Cambridge, UK, 26 May 202 6 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat' at the Jefferies New York Healthcare Conference on Wednesday,3rd June at 3:45 p.m. EDT / 4th 4:45 a.m. JST. During the event, Mr. Cargill will present the Company's strategy, recent progress and expected upcoming milestones to…

GlobeNewsWire • May 26, 2026
Nxera Pharma Announces Progress of Out-Licensing of GPCR-targeted Program and Participation in Series A Financing

Tokyo, Japan and Cambridge, UK, 11 May 202 6 – As announced on 12 February 2026, Nxera Pharma Co., Ltd. (“Nxera” or the “Company”) entered into a license agreement with a newly established company (“NewCo”) to advance a specific GPCR-targeted program owned by Nxera. Nxera today announces that, in connection with the closing of a Series A financing undertaken by NewCo, Nxera and a syndicate of leading healthcare and…

GlobeNewsWire • May 11, 2026
Nxera Files Patent Infringement Action in Relation to its miniG Platform Technology

Tokyo, Japan and Cambridge and London, UK, 8 May 2026 – Nxera Pharma Co., Ltd. (“Nxera Pharma” or “the Company”; TSE 4565) announces that its wholly owned subsidiary Nxera Pharma UK Limited (“Nxera”) has issued proceedings against OMass Therapeutics alleging infringement of its patents EP 3 408 286 B1 and GB 2 558 968 B relating to its proprietary miniG technology. miniG is an integral part of Nxera's NxWave™…

GlobeNewsWire • May 8, 2026

🧮 Earnings Move Analyzer

Insider Trading

No insider trades found for SOLTF.

No Senate trades found for SOLTF.

No House trades found for SOLTF.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top